Top

Published in:

01-10-2009 | Clinical Study - Patient Study

Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival

Authors: Charlotte Aaberg-Jessen, Karina Christensen, Hanne Offenberg, Annette Bartels, Tanja Dreehsen, Steinbjørn Hansen, Henrik Daa Schrøder, Nils Brünner, Bjarne Winther Kristensen

Published in: Journal of Neuro-Oncology | Issue 1/2009

Abstract

In colorectal cancer and breast cancer a high TIMP-1 level has been shown to correlate with a shorter overall patient survival and it has been suggested that TIMP-1 is involved in tumour invasion, proliferation and apoptosis in different types of cancers. TIMP-1 is known to be expressed in gliomas but whether TIMP-1 is a prognostic marker in gliomas has not previously been investigated. In the present study, the TIMP-1 expression was investigated immunohistochemically in 112 formalin-fixed paraffin embedded astrocytomas and related to tumour grade and overall patient survival by scoring the TIMP-1 immunoreactivity of both tumour cells and blood vessels. Moreover, TIMP-1 in situ hybridisation was performed on ten of the glioblastomas. In the vast majority of the tumours TIMP-1 protein was expressed in both tumour cells and blood vessels. In situ hybridisation for TIMP-1 mRNA on glioblastomas confirmed the immunohistochemical expression of TIMP-1. The percentage of TIMP-1 positive tumour cells and blood vessels as well as the staining intensity varied between tumours of the same grade, but the total staining score increased with tumour grade. The multivariate Cox regression test showed that glioblastoma patients with the lowest TIMP-1 expression had a significantly longer overall survival (HR (95% CI) = 3.2 (1.5–6.7), P = 0.004) when compared to the patients with higher TIMP-1 protein expression. In conclusion, this study showed that low TIMP-1 immunohistochemical expression predicts longer overall survival in glioblastoma patients, suggesting a role for TIMP-1 as a biomarker in glioblastoma.

Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245–2252. doi:10.1038/sj.onc.1205291 CrossRefPubMed

Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25:99–113. doi:10.1007/s10555-006-7893-x CrossRefPubMed

Carmichael DF, Sommer A, Thompson RC, Anderson DC, Smith CG, Welgus HG, Stricklin GP (1986) Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci USA 83:2407–2411. doi:10.1073/pnas.83.8.2407 CrossRefPubMedPubMedCentral

Stricklin GP, Welgus HG (1983) Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization. J Biol Chem 258:12252–12258PubMed

Welgus HG, Stricklin GP, Eisen AZ, Bauer EA, Cooney RV, Jeffrey JJ (1979) A specific inhibitor of vertebrate collagenase produced by human skin fibroblasts. J Biol Chem 254:1938–1943PubMed

Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32. doi:10.1016/0014-5793(92)80015-9 CrossRefPubMed

Chesler L, Golde DW, Bersch N, Johnson MD (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86:4506–4515PubMed

Wang T, Yamashita K, Iwata K, Hayakawa T (2002) Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem Biophys Res Commun 296:201–205. doi:10.1016/S0006-291X(02)00741-6 CrossRefPubMed

Porter JF, Shen S, Denhardt DT (2004) Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 90:463–470. doi:10.1038/sj.bjc.6601533 CrossRefPubMedPubMedCentral

10.

Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852PubMed

11.

Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M, Sinha CC, Thorgeirsson UP (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75:81–87. doi:10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.0.CO;2-G CrossRefPubMed

12.

Boudreau N, Sympson CJ, Werb Z, Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891–893. doi:10.1126/science.7531366 CrossRefPubMedPubMedCentral

13.

Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102:2002–2010. doi:10.1172/JCI2881 CrossRefPubMedPubMedCentral

14.

Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, Hornebeck W, Haye B, Petitfrere E (2003) Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 372:767–774. doi:10.1042/BJ20030187 CrossRefPubMedPubMedCentral

15.

Liu XW, Bernardo MM, Fridman R, Kim HR (2003) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278:40364–40372. doi:10.1074/jbc.M302999200 CrossRefPubMed

16.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA (2004) Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10:2289–2298. doi:10.1158/1078-0432.CCR-03-0360 CrossRefPubMed

17.

Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122:2050–2056CrossRefPubMed

18.

Kuvaja P, Wurtz SO, Talvensaari-Mattila A, Brünner N, Paakko P, Turpeenniemi-Hujanen T (2007) High serum TIMP-1 correlates with poor prognosis in breast carcinoma—a validation study. Cancer Biomark 3:293–300CrossRefPubMed

19.

Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brünner N, Fernebro E (2004) Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer 40:64–72. doi:10.1016/j.ejca.2003.09.019 CrossRefPubMed

20.

Joo YE, Seo KS, Kim HS, Rew JS, Park CS, Kim SJ (2000) Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 45:114–121. doi:10.1023/A:1005421713137 CrossRefPubMed

21.

Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, Miyagi Y (2006) Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer. Gastric Cancer 9:106–113. doi:10.1007/s10120-006-0362-y CrossRefPubMed

22.

Rauvala M, Puistola U, Turpeenniemi-Hujanen T (2005) Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99:656–663. doi:10.1016/j.ygyno.2005.07.009 CrossRefPubMed

23.

Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y (1994) Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 81:69–77CrossRefPubMed

24.

Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, Del MR, Beliveau R (1999) Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 17:555–566. doi:10.1023/A:1006760632766 CrossRefPubMed

25.

Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, Edwards DR (2003) Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 1:333–345PubMed

26.

Møller SN, Dowell BL, Stewart KD, Jensen V, Larsen L, Lademann U, Murphy G, Nielsen HJ, Brünner N, Davis GJ (2005) Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases-1. Tumour Biol 26:71–80. doi:10.1159/000085588 CrossRef

27.

Sørensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brünner N, Usher PA (2006) Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 54:1075–1086. doi:10.1369/jhc.5A6896.2006 CrossRefPubMedPubMedCentral

28.

Aaberg-Jessen C, Christensen K, Schrøder HD, Offenberg H, Brünner N, Kristensen BW (2008) Low tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expression in glioblastoma predicts longer patient survival, AACR Annual Meeting, Abstract # 5541

29.

Graham DI, Lantos PL (2002) Tumours of the nervous system. In: Graham DI, Lantos PL (eds) Greenfield’s Neuropathology, vol 2. Arnold, Great Britain, pp 768–1052

30.

Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon

31.

Neckelmann K, Kristensen BW, Schrøder HD (2004) Improved histopathological evaluation of gliomas using tissue fragments obtained by ultrasonic aspiration. Clin Neuropathol 23:47–52PubMed

32.

Silverman JF, Jones FD, Unverferth M, Berns L (1989) Cytopathology of neoplasms of the central nervous system in specimens obtained by the Cavitron Ultrasonic Surgical Aspirator. Acta Cytol 33:576–582PubMed

33.

Malhotra V, Malik R, Gondal R, Beohar PC, Parkash B (1986) Evaluation of histological appearance of tissues removed by cavitron ultrasonic surgical aspirator (CUSA). Acta Neurochir (Wien) 81:132–134. doi:10.1007/BF01401235 CrossRef

34.

Shi SR, Liu C, Pootrakul L, Tang L, Young A, Chen R, Cote RJ, Taylor CR (2008) Evaluation of the value of frozen tissue section used as “gold standard” for immunohistochemistry. Am J Clin Pathol 129:358–366. doi:10.1309/7CXUYXT23E5AL8KQ CrossRefPubMed

35.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. International Agency for Research on Cancer, Lyon

36.

Usher PA, Sieuwerts AM, Bartels A, Lademann U, Nielsen HJ, Holten-Andersen L, Foekens JA, Brünner N, Offenberg H (2007) Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue. Mol oncol 1:205–215CrossRefPubMed

37.

Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL (2007) Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96:903–911. doi:10.1038/sj.bjc.6603666 CrossRefPubMedPubMedCentral

38.

Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brünner N (2000) High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 6:4292–4299PubMed

39.

Yukawa N, Yoshikawa T, Akaike M, Sugimasa Y, Rino Y, Masuda M, Imada T (2007) Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 72:205–208. doi:10.1159/000112827 CrossRefPubMed

40.

Waas ET, Hendriks T, Lomme RM, Wobbes T (2005) Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 48:700–710. doi:10.1007/s10350-004-0854-y CrossRefPubMed

41.

Tomita T (1997) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology 31:150–156. doi:10.1046/j.1365-2559.1997.2160834.x CrossRefPubMed

42.

Massi D, Franchi A, Ketabchi S, Paglierani M, Pimpinelli N, Santucci M (2003) Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol 34:80–88. doi:10.1053/hupa.2003.51 CrossRefPubMed

43.

Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS (2005) Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer 113:198–206. doi:10.1002/ijc.20566 CrossRefPubMed

44.

Jones JL, Glynn P, Walker RA (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189:161–168. doi:10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2 CrossRefPubMed

45.

Sawatsubashi M, Mizokami H, Tokunaga O, Shin T (1998) Expression of MMP-1, TIMP-1, and type I collagen in laryngeal carcinoma. Mod Pathol 11:878–885PubMed

46.

Maeta H, Ohgi S, Terada T (2001) Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438:121–128. doi:10.1007/s004280000286 CrossRefPubMed

47.

Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR (2005) Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 65:898–906PubMed

48.

Davidsen ML, Wurtz S, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114–1120. doi:10.1038/sj.bjc.6603378 CrossRefPubMedPubMedCentral

49.

Li G, Fridman R, Kim HR (1999) Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59:6267–6275PubMed

50.

Jung KK, Liu XW, Chirco R, Fridman R, Kim HR (2006) Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25:3934–3942. doi:10.1038/sj.emboj.7601281 CrossRefPubMedPubMedCentral

Title: Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival
Authors: Charlotte Aaberg-Jessen
Karina Christensen
Hanne Offenberg
Annette Bartels
Tanja Dreehsen
Steinbjørn Hansen
Henrik Daa Schrøder
Nils Brünner
Bjarne Winther Kristensen
Publication date: 01-10-2009
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-9910-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Do children and adults differ in survival from medulloblastoma? A study from the SEER registry

Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases

Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas

Early metabolic responses in temozolomide treated low-grade glioma patients

Intracranial intermediate-grade meningeal melanocytoma with increased cellular proliferative index: an illustrative case associated with a nevus of Ota

Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors